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Papers published by the European Journal of Neurology reflect the broad interest of practicing
neurologists in advances in the aetiology, diagnosis and management of neurological disorders.
As a general neurology journal, the proportion of papers in the different subject areas
reasonably reflects the case load of a practising neurologist.
Stroke represents the largest proportion of papers published, including those on
pathophysiology (1-23), acute stroke management (24-47) and the outcome of patients who
have suffered stroke (48-72). Stroke is a world-wide problem, but its prevalence varies and may
reflect both the genetic and environmental contributions to stroke, both in turn reflecting the
known risk factors for stroke. It is of note that vascular risk factors were less prevalent in the
Middle East compared to the USA, with the exception of diabetes and smoking (3). Thus
targeting this Middle East population with education and lifestyle changes would appear to be
particularly relevant. The potential genetic contribution to stroke was highlighted by a study
from Sweden of young onset strokes (age<55 years), 47% had a family history (5). An
interesting finding from Korea reported that sleep duration >8 hours was significantly associated
with an increased risk for intracerebral haemorrhage that was dose dependent: 8h OR 1.57, >9h
OR 5.0 (11). The incidence of intracerebral haemorrhage appears to be declining (19), perhaps
due to better management of hypertension and other risk factors. Of concern is that there is
under anti-coagulation treatment of atrial fibrillation, a recognised risk factor for stroke (45).
The advances in our understanding of the cause, progress, management and treatments
available for multiple sclerosis have transformed the outlook for many patients with this disorder
(73-104). Recent information on risk factors includes the recognition that low vitamin D
increases risk, and that vitamin D may provide a neuroprotective effect (86, 89). An
epidemiological study from Canada found a protective effect of low socio-economic status from
developing MS, although this was not found in other countries (88).
Parkinson disease (PD) in its early years can be well managed with symptomatic dopaminergic
therapy (105-125), while other movement disorders are less satisfactorily treated126-134). The
development of motor complications is a significant limitation to the long term use of levodopa.
A community based incident cohort in Scotland found that 21.3% developed motor fluctuations
and 28.4% dyskinesias after 59 months (108). Cumulative levodopa dose, age at diagnosis and
female sex were identified as associated with motor complications, confirming previous studies
in this area. As PD progresses, parenteral therapy may be required, and this includes the use of
intestinal levodopa infusions to help control motor function and improve dyskinesias. Of a
longitudinal study of 33 levodopa infusion patients, at baseline, 3 had developed peripheral
neuropathy and 7 had subclinical neuropathy (111). At 2 years following levodopa infusion, four
patients with normal neurophysiology at baseline developed subclinical neuropathy, and a
2further seven developed a subclinical neuropathy. Peripheral neuropathy in PD is said to have a
prevalence of 55% compared to 9% in age-matched controls (110). Alpha-synuclein pathology
in the peripheral nerves may contribute, as may levodopa related metabolic disturbances such
as low vitamin B12 and B6, and increased methylmalonic acid and homocysteine. The
association with levodopa is cumulative dose related.
A significant advance in our understanding of the pathogenesis of PD has come from the
observation that mutations of the glucocerebrosidase (GBA) gene are numerically the most
important risk factor for development of the disease. Furthermore, PD patients without GBA
mutations exhibit low GBA enzyme activity resulting from accumulation of alpha-synuclein. GBA
mutations are also strongly associated with the risk for dementia with Lewy bodies, highlighting
the link between GBA and the synucleinopathies. However, the prevalence of GBA mutations in
multiple system atrophy has not been consistently found to be increased and a recent study
from Germany found no increase in progressive supranuclear palsy, primary progressive
aphasia or frontotemporal dementia, two of 39 patients with corticobasal syndrome had
mutations (116). Another genetic study in PD, focussing on the mitochondrial genome found
associations between haplotypes and both increased and reduced risk for PD (117). These
findings were supported by functional analyses using cybrids.
The neurodegenerative diseases constitute major economic and social as well as medical
challenges (135-162). The association of dementia with income, mortality, morbidity and
medication use has been highlighted with a study from Denmark (155), with effects seen years
before diagnosis. The additional healthcare costs and lost productivity prior to diagnosis was
estimated at 2082 euros per patient more than matched controls. This figure increased to 4544
euros per patient after diagnosis. In the UK, the average annual cost of caring for a patient with
Huntington’s disease is 24,000 euros, 16,000 euros of which was informal care for inside and
outside the home (161). These figures highlight the considerable potential for investing in
research to slow, stop or prevent these and other neurodegenerative diseases. Advances in our
knowledge on the genetics and environmental associations in amyotrophic lateral sclerosis
promise to provide important insights into potential strategies to reduce risk and highlight
potential treatments (163-176).
Epilepsy likewise represents another neurological disorder with significant societal and
economic consequences, as well as medical (177-190). Treatments for epilepsy have been
available for many years; a recent study on the long term prognosis of epilepsy found 59% of
patients were seizure free, with a progressive increase in remission over time (184). Thus the
long term prognosis of epilepsy is favourable, but poor prognosis for remission can be predicted
with reasonable accuracy.
Neuromuscular disorders (191-213), trauma (214-215), neuro-inflammation (216-223),
headache (224-231) and more general neurological topics (232-248) complete the 2016
spectrum of the Journal’s purview.
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